Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles

Virology Journal

Volumn 8, Issue , 2011, Pages

  Bridge, Simon H ^a,f   Sharpe, Sally A ^b   Dennis, Mike J ^b   Dowall, Stuart D ^b   Getty, Brian ^c   Anson, Donald S ^d   Skinner, Michael A ^e   Stewart, James P ^c   Blanchard, Tom J ^a,g  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

broadly reactive neutralising antibodies; cholera toxin B; fowlpox virus; human complement protein C3d; modified vaccinia virus Ankara; Prime boost HIV vaccine; recombinant poxvirus; virus like particle

Indexed keywords

BETA GALACTOSIDASE; CHOLERA TOXIN B SUBUNIT; DNA VACCINE; GAMMA INTERFERON; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; VIRUS DNA; VIRUS VECTOR; DNA; GAG PROTEIN; GLYCOPROTEIN GP 120; HETEROPHILE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE;

AFRICA; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; ENVELOPE GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FOWLPOX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MACACA FASCICULARIS; MALE; NONHUMAN; POXVIRUS; T LYMPHOCYTE; TRANSMISSION ELECTRON MICROSCOPY; VACCINIA VIRUS; VIRUS ISOLATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; GENE VECTOR; GENETIC REASSORTMENT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; VACCINATION; VIROLOGY;

FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; POXVIRIDAE; VACCINIA VIRUS ANKARA;

AIDS VACCINES; ANIMALS; ANTIGENS, HETEROPHILE; BETA-GALACTOSIDASE; DNA; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FOWLPOX VIRUS; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; MACACA FASCICULARIS; MALE; REASSORTANT VIRUSES; VACCINATION; VACCINES, DNA; VACCINES, VIRUS-LIKE PARTICLE; VACCINIA VIRUS;

EID: 80052605562     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-429     Document Type: Article

References (93)

1. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, J Infect Dis 2006 194 12 1661 1671 10.1086/508748 17109337 (Pubitemid 44901996)
2. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Lancet 2008 372 9653 1881 1893 10.1016/S0140-6736(08)61591-3 19012954
3. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, et al. Lancet 2008 372 9653 1894 1905 10.1016/S0140-6736(08)61592-5 19012957
4. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. N Engl J Med 2009 361 23 2209 2220 10.1056/NEJMoa0908492 19843557
5. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A, Dtsch Med Wochenschr 1974 99 47 2386 2392 10.1055/s-0028-1108143 4426258
6. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, Laidlaw SM, Peto T, Skinner MA, Gilbert SC, et al. Vaccine 2006 24 15 3026 3034 10.1016/j.vaccine.2005.10.058 16488059
7. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, et al. Proc Natl Acad Sci USA 2005 102 13 4836 4841 10.1073/pnas.0406381102 15781866 (Pubitemid 40471540)
8. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. Blanchard TJ, Alcami A, Andrea P, Smith GL, The Journal of general virology 1998 79 Pt 5 1159 1167 9603331 (Pubitemid 28203857)
9. Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Brown M, Zhang Y, Dermine S, de Wynter EA, Hart C, Kitchener H, Stern PL, Skinner MA, Stacey SN, Gene Ther 2000 7 19 1680 1689 10.1038/sj.gt.3301288 11083477
10. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, Hanlon M, Spencer AJ, Honeycutt JD, Wyllie DH, Gilbert SC, et al. Science translational medicine 2010 2 19 19ra12 10.1126/scitranslmed.3000490 20371486
11. Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Cottingham MG, van Maurik A, Zago M, Newton AT, Anderson RJ, Howard MK, Schneider J, Skinner MA, Clin Vaccine Immunol 2006 13 7 747 757 10.1128/CVI.00088-06 16829611
12. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, Becker M, Gilbert SC, Hill AV, Smith GL, McMichael A, The Journal of general virology 1998 79 Pt 1 83 90 9460927 (Pubitemid 28039304)
13. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A, Vaccine 1999 17 6 589 596 10.1016/S0264-410X(98) 00238-2 10075166 (Pubitemid 29071091)
14. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, et al. Science 2001 292 5514 69 74 10.1126/science.1058915 11393868 (Pubitemid 32289126)
15. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, et al. Journal of virology 1999 73 9 7524 7532 10438842 (Pubitemid 29383236)
16. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA, Journal of virology 1998 72 12 10180 10188 9811759 (Pubitemid 28520889)
17. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. Santra S, Sun Y, Parvani JG, Philippon V, Wyand MS, Manson K, Gomez-Yafal A, Mazzara G, Panicali D, Markham PD, et al. Journal of virology 2007 81 16 8563 8570 10.1128/JVI.00744-07 17553898 (Pubitemid 47242829)
18. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Seth A, Ourmanov I, Kuroda MJ, Schmitz JE, Carroll MW, Wyatt LS, Moss B, Forman MA, Hirsch VM, Letvin NL, Proc Natl Acad Sci USA 1998 95 17 10112 10116 10.1073/pnas.95.17.10112 9707609 (Pubitemid 28415303)
19. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, et al. Vaccine 2006 24 4 417 425 10.1016/j.vaccine.2005.08.041 16176847 (Pubitemid 41832544)
20. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, et al. J Infect Dis 2011 203 5 610 619 10.1093/infdis/jiq105 21282192
21. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pinheiro S, Gillespie G, Brown D, Loach V, et al. Journal of virology 2006 80 10 4717 4728 10.1128/JVI.80.10.4717-4728.2006 16641265
22. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Guimaraes-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, Barin B, McMichael A, Weber J, Legg K, et al. Vaccine 2008 26 51 6671 6677 10.1016/j.vaccine.2008.09.016 18812202
23. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hemachandra A, Puls RL, Sirivichayakul S, Kerr S, Thantiworasit P, Ubolyam S, Cooper DA, Emery S, Phanuphak P, Kelleher A, et al. Hum Vaccin 2010 6 10 835 840 10.4161/hv.6.10.12635 20864808
24. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, Dorrell L, McShane H, et al. The Journal of general virology 2004 85 Pt 4 911 919 15039533 (Pubitemid 38489556)
25. Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape. Sewell AK, Price DA, Oxenius A, Kelleher AD, Phillips RE, Stem Cells 2000 18 4 230 244 10.1634/stemcells.18-4-230 10924089 (Pubitemid 30602270)
26. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV, Nature medicine 1998 4 4 397 402 10.1038/nm0498-397 9546783 (Pubitemid 28212753)
27. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, et al. Nature medicine 2003 9 6 729 735 10.1038/nm881 12766765 (Pubitemid 36749222)
28. HIV vaccines. McMichael AJ, Annu Rev Immunol 2006 24 227 255 10.1146/annurev.immunol.24.021605.090605 16551249
29. Challenges in the development of an HIV-1 vaccine. Barouch DH, Nature 2008 455 7213 613 619 10.1038/nature07352 18833271
30. An HIV vaccine - evolving concepts. Johnston MI, Fauci AS, N Engl J Med 2007 356 20 2073 2081 10.1056/NEJMra066267 17507706 (Pubitemid 46789897)
31. Toward an AIDS vaccine. Walker BD, Burton DR, Science 2008 320 5877 760 764 10.1126/science.1152622 18467582 (Pubitemid 351929619)
32. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Walker LM, Burton DR, Curr Opin Immunol 2010 22 3 358 366 10.1016/j.coi.2010.02.012 20299194
33. The role of antibodies in HIV vaccines. Mascola JR, Montefiori DC, Annu Rev Immunol 2010 28 413 444 10.1146/annurev-immunol-030409-101256 20192810
34. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Stamatatos L, Morris L, Burton DR, Mascola JR, Nature medicine 2009 15 8 866 870 19525964
35. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, et al. Science 2009 326 5950 285 289 10.1126/science.1178746 19729618
36. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC, Science 1992 258 5090 1938 1941 10.1126/science.1470917 1470917 (Pubitemid 23026733)
37. HIV vaccine design: insights from live attenuated SIV vaccines. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, et al. Nat Immunol 2006 7 1 19 23 10.1038/ni1296 16357854 (Pubitemid 41823864)
38. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, et al. N Engl J Med 1999 340 22 1715 1722 10.1056/NEJM199906033402203 10352163 (Pubitemid 29252599)
39. Virus-like particles as a vaccine delivery system: myths and facts. Roy P, Noad R, Adv Exp Med Biol 2009 655 145 158 10.1007/978-1-4419-1132-2-11 20047040
40. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, et al. Journal of virology 2002 76 15 7625 7631 10.1128/JVI.76.15.7625-7631.2002 12097576 (Pubitemid 34760986)
41. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, Jiang P, de Vries RP, Wiley C, Zharkikh I, Schulke N, et al. Virology 2007 366 2 245 262 10.1016/j.virol.2007.04.033 17580087 (Pubitemid 47393683)
42. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Chege GK, Thomas R, Shephard EG, Meyers A, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL, Vaccine 2009 27 35 4857 4866 10.1016/j.vaccine.2009.05.064 19520196
43. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02-AG) DNA/MVA vaccines expressing mature and immature VLPs. Ellenberger D, Wyatt L, Li B, Buge S, Lanier N, Rodriguez IV, Sariol CA, Martinez M, Monsour M, Vogt J, et al. Virology 2005 340 1 21 32 10.1016/j.virol.2005.06.014 16023165 (Pubitemid 41191175)
44. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Ellenberger D, Otten RA, Li B, Aidoo M, Rodriguez IV, Sariol CA, Martinez M, Monsour M, Wyatt L, Hudgens MG, et al. Virology 2006 352 1 216 225 10.1016/j.virol.2006.04.005 16725169 (Pubitemid 44160714)
45. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. McBurney SP, Young KR, Ross TM, Virology 2007 358 2 334 346 10.1016/j.virol.2006.08.032 17011011 (Pubitemid 46138113)
46. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. McBurney SP, Ross TM, Vaccine 2009 27 32 4337 4349 10.1016/j.vaccine.2009.04.032 19389453
47. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. Robinson HL, Sharma S, Zhao J, Kannanganat S, Lai L, Chennareddi L, Yu T, Montefiori DC, Amara RR, Wyatt LS, et al. AIDS research and human retroviruses 2007 23 12 1555 1562 10.1089/aid.2007.0165 18160013
48. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L, Vaccine 2011 29 31 4903 4912 10.1016/j.vaccine.2011.05.005 21596074
49. New adjuvants for human vaccines. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R, Curr Opin Immunol 2010 22 3 411 416 10.1016/j.coi.2010.04.004 20466528
50. New adjuvants in evolving vaccine strategies. Buonaguro FM, Tornesello ML, Buonaguro L, Expert Opin Biol Ther 2011 11 7 827 832 10.1517/14712598.2011. 587802 21609186
51. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT, Science 1996 271 5247 348 350 10.1126/science.271.5247.348 8553069
52. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Ross TM, Xu Y, Bright RA, Robinson HL, Nat Immunol 2000 1 2 127 131 10.1038/77802 11248804
53. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. Green TD, Montefiori DC, Ross TM, Journal of virology 2003 77 3 2046 2055 10.1128/JVI.77.3.2046-2055.2003 12525639 (Pubitemid 36110017)
54. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, Bower JF, Ross TM, Tedder TF, J Immunol 2004 172 10 5833 5837 15128761 (Pubitemid 38621180)
55. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL, AIDS research and human retroviruses 2001 17 9 829 835 10.1089/088922201750252025 11429124 (Pubitemid 32692398)
56. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases. Langridge W, Denes B, Fodor I, Curr Opin Investig Drugs 2010 11 8 919 928 20721834
57. An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice. Bruhl P, Kerschbaum A, Eibl MM, Mannhalter JW, AIDS research and human retroviruses 1998 14 5 401 407 10.1089/aid.1998.14.401 9546799 (Pubitemid 28125698)
58. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M, J Immunol 2004 172 10 6209 6220 15128809 (Pubitemid 38621227)
59. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R, N Engl J Med 2004 350 9 896 903 10.1056/NEJMoa030595 14985487 (Pubitemid 38252537)
60. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, et al. Science 2005 308 5730 1906 1908 10.1126/science.1111781 15860590 (Pubitemid 40941873)
61. HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? Haynes BF, Nicely NI, Alam SM, Nat Struct Mol Biol 2010 17 5 543 545 10.1038/nsmb0510-543 20442740
62. Helper plasmids for production of HIV-1-derived vectors. Fuller M, Anson DS, Hum Gene Ther 2001 12 17 2081 2093 10.1089/10430340152677421 11747598 (Pubitemid 34053492)
63. Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates. Davis D, Donners H, Willems B, Ntemgwa M, Vermoesen T, van der Groen G, Janssens W, J Med Virol 2006 78 7 864 876 10.1002/jmv.20635 16721864 (Pubitemid 43856692)
64. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Montefiori DC, Mascola JR, Curr Opin HIV AIDS 2009 4 5 347 351 10.1097/COH.0b013e32832f4a4d 20048696
65. Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. Willey R, Nason MC, Nishimura Y, Follmann DA, Martin MA, AIDS research and human retroviruses 2010 26 1 89 98 10.1089/aid.2009.0144 20059398
66. Immunization with wild-type or CD4 binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous SHIV challenge. Sundling C, O'Dell S, Douagi I, Forsell MN, Morner A, Lore K, Mascola JR, Wyatt RT, Karlsson Hedestam GB, Journal of virology 2010
67. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, et al. Journal of virology 2007 81 12 6187 6196 10.1128/JVI.00239-07 17409164 (Pubitemid 46878025)
68. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Richman DD, Wrin T, Little SJ, Petropoulos CJ, Proc Natl Acad Sci USA 2003 100 7 4144 4149 10.1073/pnas.0630530100 12644702 (Pubitemid 36418171)
69. Antibody neutralization and escape by HIV-1. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Nature 2003 422 6929 307 312 10.1038/nature01470 12646921 (Pubitemid 36378357)
70. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. Hicar MD, Chen X, Briney B, Hammonds J, Wang JJ, Kalams S, Spearman PW, Crowe JE Jr, J Acquir Immune Defic Syndr 2010 54 3 223 235 10.1097/QAI. 0b013e3181dc98a3 20531016
71. Centralized HIV-1 envelope immunogens and neutralizing antibodies. Gao F, Liao HX, Hahn BH, Letvin NL, Korber BT, Haynes BF, Curr HIV Res 2007 5 6 572 577 10.2174/157016207782418498 18045113 (Pubitemid 351210991)
72. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Bower JF, Green TD, Ross TM, Virology 2004 328 2 292 300 10.1016/j.virol.2004.07.031 15464849 (Pubitemid 39349478)
73. Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner. Logan GJ, Wang L, Zheng M, Coppel RL, Alexander IE, Immunol Cell Biol 2010 88 2 228 232 10.1038/icb.2009.92 19935770
74. Effects of recombinant cholera toxin B subunit on IL-1beta production by macrophages in vitro. Maeyama J, Isaka M, Yasuda Y, Matano K, Taniguchi T, Morokuma K, Ohkuma K, Tochikubo K, Goto N, Microbiol Immunol 2002 46 9 593 599 12437026
75. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. Berkower I, Patel C, Ni Y, Virnik K, Xiang Z, Spadaccini A, Virology 2008 377 2 330 338 10.1016/j.virol.2008.03.040 18519142
76. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA, Journal of virology 2000 74 4 1961 1972 10.1128/JVI.74.4.1961-1972.2000 10644369 (Pubitemid 30434055)
77. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes. Benferhat R, Krust B, Rey-Cuille MA, Hovanessian AG, Vaccine 2009 27 27 3620 3630 10.1016/j.vaccine.2009.03.057 19464543
78. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Hovanessian AG, Briand JP, Said EA, Svab J, Ferris S, Dali H, Muller S, Desgranges C, Krust B, Immunity 2004 21 5 617 627 10.1016/j.immuni.2004.08.015 15539149 (Pubitemid 39489892)
79. HIV sensitivity to neutralization is determined by target and virus producer cell properties. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, Trkola A, AIDS (London, England) 2009 23 13 1659 1667 10.1097/QAD. 0b013e32832e9408
80. International network for comparison of HIV neutralization assays: the NeutNet report. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, et al. PloS one 2009 4 2 4505. 19229336
81. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyo EM, et al. Virology 2008 375 2 315 320 10.1016/j.virol.2008.02.007 18367229
82. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K, Morner A, Sutter G, Erfle V, Heeney JL, Wahren B, et al. The Journal of general virology 2004 85 Pt 8 2407 2419 15269383 (Pubitemid 39162614)
83. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Pavone-Cossut MR, Macchia I, Farcomeni S, Tenner-Racz K, Racz P, Ensoli B, et al. Journal of medical primatology 2007 36 4-5 180 194 10.1111/j.1600-0684.2007.00236.x 17669207 (Pubitemid 47103482)
84. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, Journal of virology 1998 72 4 2855 2864 9525605 (Pubitemid 28175522)
85. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC, Antimicrob Agents Chemother 2002 46 6 1896 1905 10.1128/AAC.46.6.1896-1905.2002 12019106 (Pubitemid 34535213)
86. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Chakrabarti S, Brechling K, Moss B, Mol Cell Biol 1985 5 12 3403 3409 3939316 (Pubitemid 16233047)
87. Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F). Qingzhong Y, Barrett T, Brown TD, Cook JK, Green P, Skinner MA, Cavanagh D, Vaccine 1994 12 6 569 573 10.1016/0264-410X(94)90319-0 8036832 (Pubitemid 24122867)
88. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, Roby CA, Kamin-Lewis R, Lewis GK, AIDS research and human retroviruses 1994 10 4 371 381 10.1089/aid.1994.10.371 8068416 (Pubitemid 24141211)
89. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. Simon JH, Fouchier RA, Southerling TE, Guerra CB, Grant CK, Malim MH, Journal of virology 1997 71 7 5259 5267 9188594 (Pubitemid 27258199)
90. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, Lerner RA, Proc Natl Acad Sci USA 1991 88 22 10134 10137 10.1073/pnas.88.22.10134 1719545 (Pubitemid 21915789)
91. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. Science 1994 266 5187 1024 1027 10.1126/science.7973652 7973652 (Pubitemid 24373715)
92. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H, Journal of virology 1996 70 2 1100 1108 8551569 (Pubitemid 26029030)
93. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, et al. AIDS research and human retroviruses 1994 10 12 1651 1658 10.1089/aid.1994.10.1651 7888224